Massachusetts Institute of Technology

Children's Medical Center Corporation

University of Washington

Sigilon Therapeutics, Inc.

Fred Hutchinson Cancer Center

Seattle Children's Hospital

Children's Medical Center Coporation

William Marsh Rice University

Fred Hutchinson Cancer Research Foundation

Omid Veiseh

Robert Samuel Langer

Daniel Griffith Anderson

Arturo Jose Vegas

Joshua C Doloff

Minglin Ma

Delai Chen

Christian J Kastrup

Miqin Zhang

Robert S Langer

Joshua Charles Doloff

Richard Glen Ellenbogen

Forrest M Kievit

Robert James Miller

Matthias Alexander Oberli

Paul Kevin Wotton

Yizhou Dong

Mandana Veiseh

Eric Andrew Appel

Samuel R Browd

James M Olson

Jordan S Miller

Robert S Langer, Jr

Raymond W Sze

Bagrat Grigoryan

Richard Heidebrecht

Matthew J Webber

Erika Ellen Johnston

Weiheng Wang

Benjamin C Tang

Chen Fang

David Peritt

Lauren Emily Barney

Michael Beauregard

Daniel G Anderson

Volkan Yesilyurt

Guillaume Carmona

William Shain

Kun Xue

Francisco Caballero Gonzalez

Siavash Parkhideh

Owen O'Connor

Brian W Hanak

Jared A Sewell

Devyn McKinley Smith

John R Silber

Zachary Stephen

Robert F Hevner

Patrik Gabikian

S-Bahram Bahrami

Sudip Mukherjee

Zoe Yin

Daniel Warren Sazer

Arturo J Vegas

Devyn Mckinley Smith

Owen O'CONNOR

Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.

Materials with improved biocompatibility

Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.

Implantable particles and related methods

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

Modified alginates for anti-fibrotic materials and applications

The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are implantable elements (e.g., devices and materials) comprising the same, as well as methods of use thereof, e.g., for treating or preventing a disease, disorder, or condition.

Compounds, devices, and uses thereof

Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates

Neurological implants whose surfaces have been chemically and covalently modified to impart beneficial properties to the neurological implants are described. The neurological implants possess improved biocompatibility compared to a corresponding neurological implant that lacks the chemical modification. Following implantation in a subject, the surface-modified neurological implants induce a lower-foreign body response, compared to a corresponding unmodified product.

Anti-inflammatory coatings to improve biocompatibility of neurological implants

Polyarginine-coated nanoparticle, and methods for making and using the nanoparticle. The nanoparticle can have a core that includes a material that imparts magnetic resonance imaging activity to the particle and, optionally, include one or more of an associated therapeutic agent, targeting agent, and diagnostic agent.

Polyarginine-coated magnetic nanovector and methods of use thereof

Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

Zwitterionic polymers or biocompatible polymers with improved properties for cell encapsulation, coating of devices, or a combination thereof are described. The biocompatible polymer contains a zwitterionic monomer, a monomer with a reactive side chain, and optionally another hydrophobic monomer or a neutral hydrophilic monomer. The zwitterionic polymers are cross-linked with a cross-linker via covalent bond to form a zwitterionic hydrogel in the presence of cells. Also provided, are methods of making and using the zwitterionic polymers.

Biocompatible coatings and hydrogels for reducing foreign body response and fibrosis

Growing community of inventors

Cambridge, MA, United States of America

Omid Veiseh